Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Cancer Drug Sales Boost Bristol-Myers Squibb Performance

By AP | October 28, 2016

NEW YORK (AP) — Bristol-Myers Squibb stock is up more than 7 percent after the drugmaker reported strong drug sales and raised guidance for the year.

The biopharmaceutical company said global revenues for the third quarter were driven by sales of the cancer drug Opdivo, which tripled to $615 million from a year ago. Sales of Eliquis, a cardiovascular medicine, rose 90 percent from a year ago to $884 million.

Bristol-Myers reported third quarter earnings of $1.2 billion, easily beating last year’s $706 million.

The New York-based company said it earned 72 cents per share in the three months ended Sept. 30, up from 42 cents per share a year earlier. Earnings, adjusted for non-recurring costs, were 77 cents per share, compared with last year’s 39 cents.

The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of 65 cents per share.

The company posted revenue of $4.92 billion in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $4.75 billion. The company had revenue of $4.1 billion for the same period last year.

Bristol-Myers expects full-year earnings in the range of $2.80 to $2.90 per share. It had previously targeted a range of $2.55 to $2.65 per share.

Bristol-Myers Squibb Co. shares rose $3.57, or 7.2 percent, to $52.86 in afternoon trading. The stock has declined almost 21 percent over the past year.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50